Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, comments on promising ibrutinib-based combinations under development for the treatment of chronic lymphocytic leukemia (CLL), including doublet therapies such as venetoclax-ibrutinib, or triplet combinations such as ibrutinib-venetoclax-obinutuzumab, and more novel strategies combining ibrutinib with bispecific antibodies. In the future, ibrutinib may be combined with newer BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть